A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Interventions
DRUG

ASP2138

Intravenously or Subcutaneously

DRUG

Pembrolizumab

Intravenously

DRUG

Oxaliplatin

Intravenously

DRUG

Leucovorin

Intravenously

DRUG

Fluorouracil

Intravenously

DRUG

Ramucirumab

Intravenously

DRUG

Paclitaxel

Intravenously

DRUG

Irinotecan

Intravenously

DRUG

Capecitabine

Oral Administration

Trial Locations (43)

10016

RECRUITING

NYU Langone Medical Center - NYU Medical Oncology Associates, New York

10032

RECRUITING

Columbia University, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

27103

RECRUITING

Wake Forest University Baptist Health, Winston-Salem

27710

RECRUITING

Duke Children's Hospital and Health Center, Durham

53226

RECRUITING

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

60611

RECRUITING

Northwestern University, Chicago

66205

RECRUITING

University of Kansas Cancer Center, Westwood

75390

RECRUITING

UT Southwestern Medical Center, Dallas

90404

WITHDRAWN

UCLA Dept of Medicine - Hematology/Oncology, Santa Monica, Santa Monica

92868

RECRUITING

University of California Irvine Medical Center, Orange

98101

RECRUITING

Virginia Mason Medical Center, Seattle

08901

COMPLETED

Rutgers Cancer Institute of New Jersey, New Brunswick

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

RECRUITING

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

RECRUITING

Site FR33005, Vaillant

RECRUITING

Site FR33003, Lyon

RECRUITING

Site FR33004, Marseille

RECRUITING

Site FR33006, Poitiers

RECRUITING

Site FR33001, Saint-Herblain

RECRUITING

Site FR33002, Toulouse

RECRUITING

Site IT39004, Milan

RECRUITING

Site IT39001, Milan

RECRUITING

Site IT39005, Rozzano

RECRUITING

Site IT39003, Verona

RECRUITING

Aichi Cancer Center, Nagoya

RECRUITING

National Cancer Center Hospital East, Kashiwa

RECRUITING

Kanagawa Cancer Center, Yokohama

RECRUITING

Kindai University Hospital, Sayama

RECRUITING

The University of Osaka Hospital, Suita

RECRUITING

National Cancer Center Hospital, Chuo-ku

RECRUITING

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku

RECRUITING

Site PR16101, San Juan

RECRUITING

Site KR82004, Seongnam-si

RECRUITING

Site KR82001, Guro-gu

RECRUITING

Site KR82002, Jongno-gu

RECRUITING

Site KR82003, Seocho-gu

RECRUITING

Site KR82005, Seodaemun-gu

RECRUITING

Site ES34002, Barcelona

RECRUITING

Site ES34007, El Palmar

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY